Find Funding Opportunities

In July of 2000 it was announced that the NIH would set aside $50 million over five years to support research on new ways to treat Alzheimer's disease, an ongoing commitment, by targeting the production of disease-associated processes, such as formation of amyloid plaques and neurofibrillary tangles with a special emphasis on the development of a vaccine to prevent the disease. This RFA is intended to assist in the development of immunological preventive and treatment strategies for Alzheimer’s disease. As part of the overall initiative, several related program announcements, with set-asides, are also being developed.

The National Gene Vector Laboratories (NGVL) were established in 1995 to produce clinical grade vectors for human gene transfer protocols. The purpose of this Request for Applications (RFA) is to continue the support of the NGVL to produce and distribute such vectors and to perform related toxicology studies for Phase I and II human clinical gene transfer protocols.

Participating Institutes and Centers (ICs) of the National Institutes of Health (NIH) invite applications for R01 awards to support Bioengineering Research Partnerships (BRPs) for basic multidisciplinary research addressing important biological or medical research problems. A BRP is a multidisciplinary research team applying an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. The partnership must include appropriate bioengineering expertise in combination with basic and/or clinical investigators. A BRP may propose discovery-driven, developmental, non-hypothesis-driven, design-directed, or hypothesis-driven research at universities, national laboratories, medical schools, large or small businesses, or other public and private entities.

This Request for Applications (RFA) solicits applications to study the development or refinement of behavioral, pharmacological or other innovative treatment interventions for individuals with autism or other autism-spectrum disorders.

The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of AIDS Research (OAR) invite applications for Specialized Neuroscience Research Programs (SNRP) on Health Disparity: HIV and the Nervous System. The purpose of this Request for Applications (RFA) is to augment and strengthen the research capabilities of faculty, students, and fellows at minority institutions by supporting the development of new, and/or the enhancement of ongoing basic and clinical neuro-AIDS related research projects and programs. These awards will be made to support individuals at minority institutions who collaborate with one or more established NIH supported investigators at research intensive organizations. Applications submitted in response to this RFA should be focused on research related to the neurological complications of HIV infection.

The Cellular Hematology Scientific Research Group, Division of Blood Diseases and Resources, NHLBI, the Hematology Program, Division of Kidney, Urologic, and Hematologic Diseases, NIDDK, and the Repair and Plasticity Program, NINDS announce the availability of a Request for Applications (RFA) on the above subject. The objective of this initiative is to promote the thorough exploration and characterization of stem cell plasticity in hematopoietic and non-hematopoietic tissue. Research efforts are needed to test stem cell plasticity in a rigorous manner. It is of particular importance to characterize cellular and molecular mechanisms that lead to the capacity of adult stem cells with hematopoietic potential to express other potentials and precursor cells of adult non-hematopoietic tissues to express hematopoietic potential. Other areas of high interest include the ability of stem cells from non-neuronal tissues to differentiate along neuronal and glial lineages.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) invite exploratory and developmental research grant applications (R21) that will broaden the base of inquiry on Facioscapulohumeral muscular dystrophy (FSHD).

The National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) invite investigator-initiated research applications for mechanistic studies in clinical trials of immunomodulatory interventions for immune system mediated diseases, including, but not limited to, asthma and allergy, graft failure in solid organ, tissue, cell and stem cell transplantation, and autoimmune diseases. Specifically, this Request for Applications (RFA) is a continuation and modification of RFA AI-00-005. It focuses on the inclusion of patients and utilization of patient samples for the evaluation of immunologic and other relevant parameters to facilitate the study and definition of immunological mechanisms underlying the intervention, the mechanisms of disease pathogenesis, surrogate/biomarkers markers of disease activity and therapeutic effect, and mechanisms of human immunologic function. The parent or core clinical trial must have independent financial support and will NOT receive support under this RFA. Proposed mechanistic studies associated with clinical trials supported by industry are particularly encouraged but clinical trials supported by any source, public or private, are eligible.

This Program Announcement (PA) is designed to solicit research projects that anticipate, analyze, and address the ethical, legal, and social implications of the discovery of new genetic technologies and the availability and use of genetic information resulting from human genetics and genomic research. Of particular interest are studies that: 1) examine the issues surrounding the completion of the human DNA sequence and the study of human genetic variation, 2) examine the issues raised by the integration of genetic technologies and information into health care and public health activities, 3) examine the issues raised by the integration of knowledge about genomics and gene-environment interactions into non-clinical settings, 4) explore the ways in which new genetic knowledge may interact with a variety of philosophical, theological, and ethical perspectives, and 5) explore how socioeconomic factors, gender, and concepts of race, ethnicity and culture influence the use and interpretation of genetic information, the utilization of genetic services, and the development of policy.

The Ethical, Legal and Social Implications of Genetic and Genomic Research (ELSI) Education Grant (R25) is a flexible program aimed at developing innovative educational approaches that will increase knowledge and understanding of genetics and genomics research and its ethical, legal and social implications. This program invites investigator-initiated R25 Grant applications that pursue a wide range of objectives such as: the development and pilot testing of short courses, multi-media continuing education tools, national forums, seminars, and/or hands-on workshops designed to educate scientists, health care professionals and the lay community. Other appropriate objectives include: the design, development and evaluation of new curriculum materials for a variety of audiences in a variety of educational settings. Given the current urgent need for health care providers who are genetically literate and knowledgeable, health professional education projects are of particular interest. Applications to this program should be focused on developing and evaluating new and innovative interventions that are designed to reach a large and diverse audience or that can be successfully exported to other institutions or learning environments.